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5-Hydroxymethylcytosine localizes to enhancer
elements and is associated with survival
in glioblastoma patients
Kevin C. Johnson1,2, E. Andres Houseman3, Jessica E. King1,2, Katharine M. von Herrmann1,2, Camilo E. Fadul4
& Brock C. Christensen1,2

Glioblastomas exhibit widespread molecular alterations including a highly distorted
epigenome. Here, we resolve genome-wide 5-methylcytosine and 5-hydroxymethylcytosine
in glioblastoma through parallel processing of DNA with bisulﬁte and oxidative
bisulﬁte treatments. We apply a statistical algorithm to estimate 5-methylcytosine,
5-hydroxymethylcytosine and unmethylated proportions from methylation array data.
We show that 5-hydroxymethylcytosine is depleted in glioblastoma compared with prefrontal
cortex tissue. In addition, the genomic localization of 5-hydroxymethylcytosine in
glioblastoma is associated with features of dynamic cell-identity regulation such as
tissue-speciﬁc transcription and super-enhancers. Annotation of 5-hydroxymethylcytosine
genomic distribution reveal signiﬁcant associations with RNA regulatory processes, immune
function, stem cell maintenance and binding sites of transcription factors that drive cellular
proliferation. In addition, model-based clustering results indicate that patients with
low-5-hydroxymethylcytosine patterns have signiﬁcantly poorer overall survival. Our results
demonstrate that 5-hydroxymethylcytosine patterns are strongly related with transcription,
localizes to disease-critical genes and are associated with patient prognosis.
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lioblastoma is the most common and malignant primary
intracranial tumour accounting for B60% of gliomas in
adults1. Glioblastomas are high-grade gliomas (World
Health Organization grade IV) that invade surrounding brain
tissue, quickly develop resistance to therapy and have a median
survival of 16–19 months after treatment with surgery, radiation
and chemotherapy2.
Systematic molecular analyses have advanced our
understanding of glioblastoma pathobiology through the
identiﬁcation of common mutations, structural-based genetic
alterations and dysregulated epigenomes3–5. Among these
molecular alterations, severe disturbance of the glioblastoma
epigenome has been observed, especially perturbations to global
DNA 5-methylcytosine (5 mC) patterns6–9. Importantly, DNA
methylation alterations have been recognized to have a functional
impact on glioblastomagenesis, tumour growth, response to
therapy and prognosis3,7,10,11. Similar to other tumour types,
glioblastomas exhibit patterns of genome-wide 5 mC loss and
genomic context-speciﬁc DNA hypermethylation when compared
with healthy nervous tissues12. Epigenomic patterns in cancer are
often heterogeneous and can be substantially inﬂuenced by the
presence of genetic alterations. For example, gliomas that carry
mutations in the isocitrate dehydrogenase 1 and 2 (IDH1 and
IDH2) genes have been shown to harbour a pattern of DNA
hypermethylation at certain promoter regions which results in a
glioma CpG island methylator phenotype (G-CIMP)8. The
epigenomic phenotype of G-CIMP tumours has been associated
with distinct copy number alterations, molecular subgroups and a
survival advantage in patients with glioblastoma7,8,13.
While the glioblastoma DNA methylome has begun to be
described, additional modiﬁcations to DNA that modulate
normal gene function have been implicated in disease development14. Indeed, the ten–eleven translocation (TET) family of
proteins have been shown to function as enzymes capable of
altering the methylation status of DNA by converting 5 mC to
5-hydroxymethylcytosine (5 hmC)14. Emerging evidence has
suggested that 5 hmC: localizes to sites of DNA damage, may
act as a transient intermediate in the process of 5 mC
demethylation, and may serve as a functional epigenetic mark
for regulating transcription15,16. In cell lines, 5 hmC has been
shown to recruit DNA-binding proteins and 5 hmC production
has been reported to be essential for glioblastomagenesis17.
However, the aetiologic, distribution and prognostic signiﬁcance
of 5 hmC levels in glioblastoma remains unclear. Accordingly,
a portrait of both 5 mC and 5 hmC patterns at a nucleotide
resolution is necessary for a more complete understanding of the
cytosine modiﬁcations in glioblastoma.
Use of sodium bisulﬁte (BS) treatment followed by hybridization to the Inﬁnium DNA methylation arrays (that is, 450 K
array) is a common method for interrogating DNA methylation
at the single base level5. However, sample treatment with sodium
BS does not allow disambiguation of 5 mC from 5 hmC.
Oxidation of 5 hmC to 5-formylcytosine (5 fC) is achievable
with potassium perruthenate treatment, and subsequent sodium
BS treatment (oxBS) converts 5 fC and cytosine to uracil and
ultimately thymine while only 5 mC remains unconverted by the
coupled oxBS treatment18. As a result, the selective oxidation step
enables disambiguation of 5 hmC from 5 mC measurements19,20.
Recently, it has been demonstrated that use of paired BS and
oxBS treatment on the same samples followed by hybridization to
the Inﬁnium DNA methylation array reliably permits accurate
quantiﬁcation of 5 hmC and 5 mC19,20.
Here, we present the characterization of 5 mC and 5 hmC levels
from paired BS and oxBS 450 K assays in thirty glioblastomas. To
effectively analyze and interpret this data, we develop and apply a
novel algorithm, OxyBS21, and produce the ﬁrst epigenome-wide
2

characterization of 5 hmC in glioblastoma. We demonstrate that
the glioblastoma genome is globally depleted of 5 hmC and its
distribution is dependent on genomic context. We also observe an
enrichment of 5 hmC at glioblastoma-speciﬁc enhancer elements,
alternative mRNA splicing events, and localization of 5 hmC to
several genes signiﬁcantly mutated in glioblastoma. In contrast to
the more commonly described repressive nature of 5 mC, 5 hmC
levels in our cohort are primarily positively associated with
gene expression and open chromatin. Finally, we ﬁnd that
pattern-speciﬁc loss of 5 hmC is associated with poor clinical
outcome in patients with glioblastoma.
Results
Estimation of 5 mC and 5 hmC. We adapted the BS–oxBS
technology to DNA from 30 glioblastomas and applied a novel
algorithm, OxyBS, to obtain genome-wide 5 hmC and 5 mC
estimates21. All samples were primary tumours, fresh frozen and
IDH1 and IDH2 wild type. Patient demographic, tumour
characteristics and survival data are presented in Table 1. Here,
we focused on the identiﬁcation of 5 hmC distribution and
abundance to better understand the role of 5 hmC in glioblastoma
pathobiology. Our approach to investigate potential functions of
5 hmC included assessment of ﬁve aims (Supplementary Fig. 1):
(1) to characterize genomic abundance and distribution of 5 hmC
and 5 mC, (2) to delineate high 5 hmC CpGs in glioblastoma,
(3) to determine functional annotation of regions with high
5 hmC, (4) to assess the impact of 5 hmC on gene expression
(5) and to apply a machine learning algorithm to cluster patients
by 5 hmC proﬁles.
Global content and genomic distribution of 5 hmC and 5 mC.
First, to qualitatively assess the extent of deregulation in the
glioblastoma epigenome we compared the total genomic content
of 5 hmC among glioblastoma samples with levels of 5 hmC in the
prefrontal cortex. Although we were unable to obtain matched
disease-free cortex samples in our own cohort, we accessed
publicly available prefrontal cortex data using the same BS–oxBS
protocol in an independent population of individuals that presented with no evidence of neurological impairment (GSE74368,
n ¼ 5). To avoid limitations due to the presence of multiple cell
types (that is, glial and neuronal) in the prefrontal cortex samples
we did not compare CpG-speciﬁc differences in 5 hmC. However,
Table 1 | Patient demographics and tumour characteristics.
Patient and tumour characteristics
Age at diagnosis (Years)
Median
Range
Sex, no (%)
Male
Female
Survival (months)
Median
Range

(n ¼ 30)
67
34–84

18 (60.0%)
12 (40.0%)

9.8
o1–53

IDH1 mutation status, no (%)
No
Yes

30 (100%)
0 (0.0%)

IDH2 mutation status, no (%)
No
Yes

30 (100%)
0 (0%)
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to provide a global perspective on 5 hmC differences we examined
the overall proportion of 5 hmC in total cytosine content (that is,
summed 5 hmC beta-values across all CpGs within each sample
divided by total number of CpGs proﬁled) between the two
tissues. We observed an average 3.5 fold reduction (P ¼ 6.2E-06,
Wilcoxon rank sum test) in the total 5 hmC content in
glioblastoma samples when compared with cortex samples
(Supplementary Fig. 2A). While all glioblastoma samples exhibited a decreased level of total 5 hmC there was high variability in
total 5 hmC loss across tumours. Potential biological explanations
that may account for the variability of total 5 hmC include sample
differences in cellular proportions and differences in the expression of the TET enzymes. To this end, we estimated putative
cellular proportions from DNA methylation data (‘Methods’
section) using a non-negative matrix factorization approach
(RefFreeEWAS) and found that there were stable estimates of
tumour purity across samples (Supplementary Fig. 3A). Thus,
differences in 5 hmC levels across tumours may be more strongly
associated with the molecular alterations across tumours rather
than tumour purity (Supplementary Fig. 3B). We next tested
whether the overall proportions of 5 hmC in total cytosine content were associated with the expression of TET enzymes and
additional epigenetic enzymes (that is, TET1, TET2, DNMT3A,
IDH1, etc). Again, we did not observe any signiﬁcant relationships (P40.05, Spearman’s rho test, Supplementary Table 1)
consistent with prior studies22. Finally, we note that the levels of
5 hmC were not signiﬁcantly associated with total 5 mC content
(Supplementary Fig. 2B, P ¼ 0.18, linear regression). 5 hmC has
been implicated in the DNA demethylation pathway and may
suggest functionality of 5 hmC outside simply removal of 5 mC.
At the nucleotide level, the dynamic range of 5 hmC detection
was between 0.00 and 0.99 on the beta-value scale. Empirical
cumulative density plots for both mean 5 hmC and 5 mC across

a

all subjects revealed near zero 5 hmC levels in a majority of CpGs
and revealed the well-established bimodal distribution for 5 mC
(Fig. 1a). To assess the site-speciﬁc relationship between 5 hmC
and 5 mC levels we computed Spearman correlation coefﬁcients
for each CpG and observed that moderate negative correlations
exist for a large majority of CpGs, and that o20% of CpGs
demonstrated weak positive correlations between 5 hmC and
5 mC (Fig. 1b). There are known differences in the distribution of
DNA methylation based upon by genomic context23. The
dependency of 5 mC levels upon CpG density was observed in
glioblastoma and the CpG islands and CpG island shores
exhibited demonstrably lower levels of 5 mC (Fig. 1c). To
determine whether potential CpG density speciﬁc patterns also
exist for 5 hmC we next computed the proportions of
CpG-speciﬁc mean 5 hmC across the four strata of CpG Island,
Shores, Shelves and Ocean. Figure 1d displays the distributions of
mean 5 mC and 5 hmC as well as statistical assessment over each
of the CpG strata. Generally, the patterns of 5 hmC levels were
similar to 5 mC and the lowest levels of 5 hmC were found across
CpG islands and CpG Island shores. Similar to observations in
5 mC, CpG Island shelves and Ocean regions also harboured the
highest levels of 5 hmC. The role of 5 mC in regulating gene
expression has best been described for promoter regions and it is
known that TET1, which catalyzes the oxidation of 5 mC to
5 hmC, is enriched for binding to DNA at CpG island
promoters24. To examine the overall distribution of mean 5 mC
and 5 hmC across the promoter regions for both cortex tissue and
glioblastomas we averaged the cytosine modiﬁcations over a four
kilobase pair window near transcriptional start sites23. We noted
the occurrence of hypermethylation (5 mC) across glioblastoma
promoter regions and a consistently lower level of glioblastoma
5 hmC proximal to promoter regions when compared with
healthy tissue (Fig. 2a,b).
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Figure 1 | 5hmC is depleted and uniquely distributed in glioblastoma. (a) Empirical cumulative distribution of mean 5-hydroxymethylcytosine (5hmC)
and 5-methylcytosine (5mC) across thirty glioblastomas. (b) Cumulative proportions of Spearman correlation coefﬁcients calculated for CpG-speciﬁc
across thirty glioblastomas. (c) Percentiles of mean 5mC beta-values for glioblastomas (n ¼ 30) across CpG Island strata. Percentiles (that is, quintiles)
shown were selected arbitrarily to highlight a large range of values and signiﬁcant differences between beta-values across the genomic regions at these
percentiles were evaluated by Kruskal-Wallis hypothesis tests. Statistical signiﬁcance (Po8.3E-03, Bonferroni adjusted alpha) is indicated with a *.
(d) Percentiles of mean 5hmC in glioblastomas (n ¼ 30) across CpG Island strata with statistical assessment via Kruskal-Wallis tests.
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Figure 2 | Promoter region 5hmC and 5mC in cortex and glioblastoma.
(a) Heat maps represent 5hmC and 5mC levels for 450K array CpGs across
4,000 base pair window in glioblastoma (n ¼ 30) and prefrontal cortex
(n ¼ 5) promoter regions. (b) Mean 5hmC and 5mC averages with þ /  2
kilo base pairs around canonical transcriptional start sites for glioblastoma
(n ¼ 30) and prefrontal cortex (n ¼ 5).

5 hmC is uniquely distributed in the glioblastoma genome. To
determine which 5 hmC sites had the highest potential functional
relevance we calculated the mean 5 hmC for each CpG across all
thirty tumours to identify CpG sites with the highest proportion
of 5 hmC alleles (Supplementary Fig. 4). In glioblastoma,
a large number of CpGs demonstrated mean 5 hmC values near
zero while signals 45% 5 hmC were found in B35,000 CpGs
(Supplementary Fig. 4). However, to be conﬁdent in distinguishing signal from background we then deﬁned CpGs as high
5 hmC CpGs if they were in the highest 1% of mean 5 hmC level;
resulting in 3,876 CpGs with a mean value of at least B9.0%
5 hmC that we described here as ‘high 5 hmC CpGs’ and are
used in subsequent analyses. Among high 5 hmC CpGs,
60% were recurrent across a majority of the thirty glioblastomas
(2,347/3,876 CpGs with at least 15 tumours displaying B9%
5 hmC at a given CpG) while 30% (1,162/3,876 CpGs) were also
among the 1% most variable 5 hmC probes suggesting greater
inter-individual variability at these locations. The complete list of
the high 5 hmC CpGs with genomic location, CpG-speciﬁc mean
4

and s.d. is provided as a resource in Supplementary Data 1. The
dynamic regulation of DNA methylation for cell-identity is a
balance between methylation and demethylation25. Here, we
visualized the CpG-speciﬁc relationships between high 5 hmC
and 5 mC at these high 5 hmC CpGs (Fig. 3a) and observed that
the highest levels of 5 hmC track to sites with intermediate levels
of 5 mC. These results are consistent with the notion that 5 hmC
may function as an intermediate in the DNA demethylation
process at dynamically regulated regions. Together, the observed
loss of 5 hmC that occurs in glioblastoma may also reﬂect
disruption of regulated genomic DNA methylation patterns.
Previous sequencing studies in non-diseased tissue have shown
that 5 hmC marks tend to reside in intronic and gene regulatory
regions26,27. However, the localization of 5 hmC in the
glioblastoma genome remains obscure and may inﬂuence
disease-critical gene expression programs. The genomic
distribution of high 5 hmC CpGs relative to canonical
transcriptional start sites (TSS) is presented in Fig. 3b and
reveals that B75% of high 5 hmC were found beyond the 5 kb
region upstream of the TSS. To determine whether elevated levels
of 5 hmC were associated with genomic features, we used
a Cochran–Mantel–Haenszel test with binary outcomes
(for example, genomic region of interest versus other) to provide a
measure of enrichment that permitted stratiﬁcation by CpG
density (that is, CpG islands, shores, shelves and ocean).
We observed that high 5 hmC CpGs were more likely to be
found in intronic regions (2.12 odds ratio (OR), P ¼ 1.7E-112,
Cochran–Mantel–Haenszel test, Fig. 3c) as well as depleted in
promoter regions (OR ¼ 0.69, P ¼ 4.8E-21, Cochran–Mantel–
Haenszel test, Fig. 3c) when the genomic regions of the 450 K
array were used as a background. These ﬁndings concur with
previous observations in non-diseased tissue28,29. Leveraging
publicly available histone H3 lysine 27 acetylation (H3K27ac)
genome-wide maps, which marks active enhancers, from three
primary glioblastomas we observed substantial enrichment for
enhancer regions among the high 5 hmC CpGs for all three
tumours (median OR ¼ 3.1, P ¼ 1.9E-211, Cochran–Mantel–
Haenszel test, Fig. 3c). Interestingly, we also found a signiﬁcant
enrichment of high 5 hmC CpGs at glioblastoma cell line (U87)
deﬁned enhancers (OR ¼ 2.2, P ¼ 1.7E-46, Cochran–Mantel–
Haenszel test, Fig. 3c) and super-enhancers (OR ¼ 3.00,
P ¼ 9.7E-63, Cochran–Mantel–Haenszel test, Fig. 3c).
Super-enhancers are a subset of enhancers that have critical
functions in deﬁning cell-identity and are frequently found at key
oncogenic drivers providing support that 5 hmC may play key
roles in disease30. We also noted that there was a modest
enrichment among high 5 hmC CpGs for glioblastoma
DNase hypersensitivity sites, a marker of open chromatin
(OR ¼ 1.32, P ¼ 5.34E-7, Cochran–Mantel–Haenszel test,
Fig. 3c). Furthermore, co-localization of 5 hmC with Polycomb
repressive complex 2 has been established in embryonic stem
cells, but has not been observed in differentiated cells31. Similarly,
we found no association between 5 hmC sites and enrichment for
Polycomb group protein target genes in glioblastomas
(OR ¼ 0.96, P ¼ 0.48, Cochran–Mantel–Haenszel test, Fig. 3c)31.
Enrichment of genomic regions among critical gene sets. To
provide a broader interpretation of 5 hmC function we next
sought to identify enrichment of high 5 hmC within speciﬁc gene
sets. To this end, we used the genomic coordinates of high 5 hmC
CpGs as a query set of regions and tested for enrichment against
the background of all CpGs present on the 450 K array in a
Genomic Regions Enrichment of Annotations Tool (GREAT)
analysis. The top twenty most highly signiﬁcant gene sets ranked
by fold enrichment are presented in Table 2. The high 5 hmC
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Figure 3 | 5hmC in glioblastoma is enriched at gene regulatory regions. (a) 5hmC-5mC scatterplot for the highest 5hmC CpGs (n ¼ 3,876) with smooth
curve ﬁtted by loess across thirty glioblastomas. Each point represents a single CpG per tumour with the highest intensity values represented in red and
lower intensity (that is, fewer signals) represented in blue. (b) The distribution of high 5hmC CpGs relative to the nearest canonical transcriptional start site
(TSS) in kilo base pairs with category bins for genomic distance shown for both upstream and downstream of the TSS. Percentage of high 5hmC CpGs
(n ¼ 3,876) are shown above each proportion. (c) Forest plot of odds ratios and 95% conﬁdence intervals (Cochran-Mantel-Haenszel or Fisher’s exact
test) for enrichment of high 5hmC genomic regions against 450K background set. Numerical representation of the odds ratio and associated P-value for
each genomic feature are also presented.

Table 2 | GREAT functional enrichment analysis of genomic regions for high 5 hmC CpGs (n ¼ 3,876).
GO: biological process
Negative regulation of receptor catabolic process
Regulation of cellular ketone metabolic process by regulation of transcription from RNA polymerase II promoter
Positive regulation of cardiac muscle hypertrophy
Cytokine production involved in immune response
Regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay
Positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay
Viral genome replication
Positive regulation of mRNA catabolic process
Regulation of histone deacetylation
Regulation of protein deacetylation
Production of molecular mediator of immune response
Regulation of mRNA stability
Regulation of RNA stability
Peptidyl-threonine modiﬁcation
Somatic stem cell maintenance
Regulation of fat cell differentiation
Protein import into nucleus
Notch signalling pathway
Nuclear import
Positive regulation of response to external stimulus

Hyper fold
enrichment
12.37
4.94
4.73
4.72
4.05
3.93
3.82
3.72
3.45
3.17
3.14
3.13
3.1
2.92
2.25
2.24
2.11
2.09
2.08
2.05

Hyper FDR
Q value
1.81E  08
1.66E  10
1.84E  08
9.42E  09
3.25E  10
4.65E  09
2.85E  08
3.21E  09
3.11E  10
6.43E  10
6.15E  12
2.51E  11
1.65E  12
1.71E  08
4.14E  09
7.68E  11
2.68E  09
9.38E  13
4.12E  09
1.72E  11

FDR, False discovery rate; GO, Gene ontology.
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Figure 4 | Biological interpretation of genomic regions with high 5hmC.
Signiﬁcance of overlap between high 5hmC regions in glioblastoma with
binding sites of transcription factors proﬁled by ENCODE. The top 10
enriched transcription factors (TFs) as obtained by LOLA analysis are
shown. TF are plotted on the x-axis sorted by TF Q-values (Fisher’s exact
test, corrected for multiple hypotheses testing of 689 TFs) on the y-axis.
The log odds ratio for each TF is represented by bubble size and the cell line
in which the ChIP-seq experiment was conducted is indicated by bubble
colour.

CpGs overlapped signiﬁcantly with diverse biological pathways
including regulation of RNA catabolism and stability, immune
response and somatic stem cell maintenance. Enrichment of RNA
stability gene sets may reﬂect shared biological processes of
5 hmC between healthy cells and cancer cells as a prior report on
adult liver 5 hmC made similar observations26. In contrast, it is
possible that gene sets involved in the immune response and stem
cell maintenance are driven by the presence of tumour inﬁltrating
lymphocytes. To validate our pathway enrichment ﬁndings we
applied an agnostic consensus clustering approach to biological
pathways deﬁned in the Kyoto Encyclopedia of Genes and
Genomes (KEGG), which considered all 5 hmC CpGs on the
array. We observed that gene sets involved with metabolism,
immunity and RNA processing functions displayed the highest
levels of 5 hmC (Supplementary Fig. 5A–C).
It has previously been observed that 5 hmC is located near
transcription factor binding sites (TFBSs) in the mammalian
genome32. To identify whether particular transcription factors are
associated with patterns of high 5 hmC we tested for enrichment
in binding sites from 689 transcription factor experiments
(ENCODE) using the Locus Overlap Analysis (LOLA)
software33. Relative to genomic regions of the 450 K array, high
5 hmC sites were signiﬁcantly associated with sixty-nine TFBSs
(Q-valueo0.05, Fisher’s exact test, Supplementary Data 2). The
top ranked TFBSs enrichments are ranked and the original cell
line in which they were proﬁled is presented in Fig. 4 and
the complete rankings can be found in Supplementary Data 2.
Several of these transcription factors have established roles in
oncogenesis including c-Fos and c-Jun as regulators of cell
proliferation and survival, whereas the co-activator p300 is
typically found at enhancer regions34,35
5 hmC localizes to genes actively transcribed in glioblastoma.
The robust enrichment for 5 hmC sites in super-enhancers and
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binding sites of proliferation-associated TFs suggests that 5 hmC
is strongly associated with regulation of disease-speciﬁc gene
expression programs. To conﬁrm that 5 hmC marks are generally
associated with active expression in glioblastoma we interrogated
the entire glioblastoma transcriptome using RNA sequencing
expression levels from The Cancer Genome Atlas (TCGA)
(n ¼ 172)13. Genes were then segregated into the three groups of
lowly, moderately or highly expressed genes based on expression
tertiles and we tested enrichment for 5 hmC sites against the
background of the 450 K array. A signiﬁcant enrichment was
found for genes that are actively transcribed in glioblastomas
(P ¼ 5.2E-139, w2 test, Supplementary Table 2). Prior evidence
has suggested a role for 5 hmC in the regulation of alternative
transcript splicing in normal tissues28. To examine whether a
similar process occurs in cancer, we leveraged the
TCGASpliceSeq database for glioblastoma-speciﬁc alterations in
mRNA splicing patterns of RNAseq data36. We found that 5 hmC
is signiﬁcantly enriched for exon skip (OR ¼ 2.03, P ¼ 2.23E-48,
Fisher’s exact test, Supplementary Table 3) and alternate
promoter events (OR ¼ 2.06, P ¼ 9.75E-35, Fisher’s exact test,
Supplementary Table 3), but observed neither an enrichment nor
depletion in retained introns (OR ¼ 0.95, P ¼ 6.3E-01, Fisher’s
exact test, Supplementary Table 3) or alternate donor sites
(OR ¼ 1.12, Fisher’s exact test, Supplementary Table 3).
We next investigated whether gene expression of candidate
genes, within our own cohort, were associated with high 5 hmC
(‘Methods’ section) using the NanoString nCounter technology.
For our candidate gene approach we selected 14 genes with a high
proportion of high 5 hmC sites in a given gene region
(Supplementary Data 3) and a gene with an established relationship to glioblastoma survival, MGMT (Supplementary Data 4). In
general, 5 hmC sites exhibited positive associations with gene
expression in our data set (Fig. 5a). In contrast, 5 mC at these
locations demonstrated primarily negative associations (Fig. 5b).
MGMT methylation has been used as a biomarker of response to
alkylating agents in glioblastoma patients11. We found that
5 hmC was not associated with MGMT expression, but conﬁrmed
the strength of association between 5 mC and MGMT expression
(Supplementary Fig. 6). Overall, the strongest association between
5 hmC and gene expression among the candidate genes was found
in the TSS1500 region of the long non-coding RNA SOX2-OT
(Spearman correlation coefﬁcient ¼ 0.62, Fig. 5c,d, Supplementary
Data 5). Notably, there was no signiﬁcant association between
5 mC and gene expression at this genomic location (Spearman
correlation coefﬁcient ¼  0.18, Fig. 5e). Finally, given our
observation that 5 hmC was associated with splicing patterns
from the TCGA we next assessed whether CpG-speciﬁc 5 hmC
was associated with the differential expression of gene transcript
variants from seven genes with high 5 hmC in gene regulatory
regions (Supplementary Data 4). In our candidate list, CpGs did
not exhibit signiﬁcant associations between differential expression
of transcript variants and 5 hmC levels (Supplementary Data 6).
Taken together, we conclude that 5 hmC is often positively
correlated with expression and may, in speciﬁc gene contexts, be
associated with alternative mRNA transcript splicing.
5 hmC proﬁles are associated with patient survival. Prior
publications have identiﬁed an association between decreased
total 5 hmC (determined by different methods) and poorer
survival in glioblastoma patients37. Although the tumours we
proﬁled were IDH1 and IDH2 wild type, we conﬁrmed that one
sample was G-CIMP þ as deﬁned in Noushmehr et al.8
(Supplementary Fig. 7). Patients with G-CIMP þ tumours have
a younger age at diagnosis and signiﬁcantly improved survival
(independent of age)10. As a result, this sample was excluded
from our survival analyses. To investigate the relation of 5 hmC
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Figure 5 | 5hmC is positively associated with gene expression. (a) 5hmC sites (that is, CpG position) relative to gene feature are plotted against
correlation coefﬁcient derived from Spearman correlations of CpG-speciﬁc 5hmC and gene expression. The size of each bubble point represents the
nominal statistical signiﬁcance of the given Spearman correlation with an increasing bubble size corresponding to a smaller P-value. The colour of each
bubble refers to a distinct gene region. All numerical 5hmC-gene expression correlation coefﬁcients and P-values are presented in Supplementary Data 5.
(b) For each 5hmC site, the correlation between 5mC and candidate gene expression was plotted. Bubble point size also reﬂects the increasing strength of
association based on Spearman correlation. All numerical 5mC-gene expression correlation coefﬁcients and P-values are also presented in Supplementary
Data 5. (c) The genomic location and context of the CpG (cg02417857, 5hmC value) most signiﬁcantly associated with gene expression mapped to within
1,500 bp of SOX2-OT transcription start site. Alternative transcripts, CpG island locations, and DNase hypersensitivity sites from the UCSC genome
browser are presented. (d) 5hmC levels at cg02417857 were signiﬁcantly positively correlated with SOX2-OT expression (n ¼ 23, P ¼ 0.002). (e) 5mC
levels at cg02417857 were not signiﬁcantly associated with SOX2-OT expression (n ¼ 23, P ¼ 0.40).

patterns (that is, not total 5 hmC) with survival we used a modelbased clustering method, Recursively Partitioned Mixture Model
(RPMM). RPMM has been extensively used for clustering DNA
methylation data to identify classes of tumours based upon 5 mC
values, including TCGA38–40. Here we applied RPMM to the
3,876 high 5 hmC CpGs and the resulting clustering solution
contained two distinct clusters, deﬁning a low and a high 5 hmC
cluster (Fig. 6a). Separate clustering analyses were performed for
the 1,000, 2,000, 3,000 and 4,000 highest 5 hmC CpGs to examine
classiﬁcation sensitivity and we observed complete stability of
cluster membership (that is, samples remained in either low
or high 5 hmC clusters regardless of CpG number selected).
Cluster membership was associated with total 5 hmC amount
(P ¼ 2.0E-04, Kruskal–Wallis rank sum test), and patient age
(P ¼ 0.03, Kruskal–Wallis rank sum test), but not copy number
alterations (P40.05, Fisher’s exact test, Supplementary Fig. 8).
The cluster of patients with low-5 hmC tumours had an older
age at diagnosis (median age ¼ 74.3 years) compared with the
high 5 hmC cluster (median age ¼ 65.2 years) and had a shorter

median survival (median overall survival ¼ 2.2 months) when
compared with the high 5 hmC cluster (median overall
survival ¼ 14.5 months). A multivariable Cox proportional
hazards model adjusting for age at diagnosis and patient sex
resulted in a signiﬁcantly increased hazard of death related with
membership in the low-5 hmC cluster independent of age (Hazard
Ratio ¼ 3.3, CI 95% 1.3–8.2, P ¼ 0.03, Cox proportional hazards
regression, Fig. 6b,c). To compare with prior work that has
measured total 5 hmC, we also constructed an index of total
5 hmC by taking the mean across all CpGs considered in the
present analysis (n ¼ 387,617) and segregated subjects into low
and high-total 5 hmC groups based on whether total 5 hmC levels
were above or below the median. In a multivariable Cox
proportional hazards model adjusted for age at diagnosis and
sex, the low total 5 hmC group was not signiﬁcantly associated
with survival (HR ¼ 0.94 CI 95% (0.43–2.03), P ¼ 0.88, Cox
proportional hazards regression) suggesting that the genomic
location of 5 hmC is an important consideration in associations
with disease progression.
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Figure 6 | Glioblastoma 5hmC clusters are associated with survival. (a) Recursively Partitioned Mixture Model (RPMM) of tumour samples based on
highest 5hmC CpGs (n ¼ 3,876 CpGs). In the heat map, each row represents a single CpG and each column represents a single tumour sample. Low and
High 5-hydroxymethylcytosine proﬁle clusters are indicated by colour (Low 5hmC ¼ red, High 5hmC ¼ blue) and are separated by a dotted red line. Total
5hmC content (quantiﬁed by the mean level of 5hmC within each tumour sample) and subject age are presented as continuous variables with intensity of
colour representing the minimum and maximum values in the population of glioblastomas (n ¼ 30). Cluster membership was associated with total 5hmC
amount (P ¼ 2.0E-04, Kruskal-Wallis rank sum test), and patient age (P ¼ 0.03, Kruskal-Wallis rank sum test). (b) Kaplan-Meier survival plot for RPMM
clusters of low 5hmC and high 5hmC. (c) Multivariate Cox proportional hazard ratios for survival based on RPMM cluster membership adjusted for subject
age and sex.

Discussion
In this study, we leveraged paired oxBS and BS 450 K arrays to
delineate the genomic location and abundance of 5 hmC at
nucleotide resolution in thirty primary glioblastomas. To the best
of our knowledge, the investigation of 5 hmC genomic distribution in glioblastoma is novel. Use of 5 hmC and 5 mC proﬁling
has permitted us to observe that the glioblastoma genome is
relatively depleted of 5 hmC when compared with healthy cortex
tissue, a ﬁnding consistent with studies that used less sensitive
techniques37,41–44. We move beyond previous studies to report
that despite global 5 hmC reduction45, the genomic regions with
elevated 5 hmC are strongly associated with active transcription
and may be important for malignant cellular processes. Overall,
our study provides evidence that a perturbed hydroxymethylome
in glioblastoma may reﬂect progressive disruption of genomic
stability and that loss of 5 hmC regulation is a potential indicator
of disease progression.
Previous efforts to characterize genome-wide DNA methylation in glioblastomas using the 450 K DNA methylation
arrays have demonstrated an association between an altered
8

epigenetic state and glioblastoma tumour biology5,8. However,
traditional BS treatment of DNA proﬁled on 450 K arrays
alone is unable to disambiguate 5 hmC from 5 mC abundance.
Existing methods to quantify the abundance of 5 hmC range from
immunohistochemistry (IHC) to liquid chromatography–mass
spectrometry (LC–MS) to sequence-based approaches. Both
immunohistochemistry and LC–MS approaches have
demonstrated that there is a depletion of 5 hmC in
glioblastomas, but these techniques are unable to discern the
genomic location of the 5 hmC conservation or loss37,42–44. In
contrast, sequencing-based approaches have the ability to detect
5 hmC at the single base resolution genome-wide, but suffer from
high costs that limit applicability in larger studies. To date, we are
not aware of any genome-wide sequencing data for 5 hmC in
glioblastoma. Notably, reduction in the complexity of the genome
sequence consequent to BS modiﬁcation results in increased
sequencing costs46. The application of the oxBS and BS protocol
for 450 K arrays represents an opportunity to strike a balance
between genomic resolution of 5 hmC and sample throughput.
Importantly, the use of paired oxBS and BS 450 K arrays has
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consistently been shown to distinguish 5 hmC from both 5 mC
and 5 C (refs 19,20,47).
Genome-wide loss of 5 hmC in cancer has been a widely
observed, yet poorly characterized biological phenomenon16,44.
The depletion of 5 hmC across several tumour types, including
glioma, suggests that loss of 5 hmC regulation is one of the many
deﬁning features of tumorigenesis41. Importantly, several studies
have noted that loss of 5 hmC is associated with increased
expression of proliferation markers and with increasing tumour
grade suggesting that loss of epigenetic regulation via 5 hmC
may contribute to disease progression37,43. The link between
decreasing 5 hmC with increasing tumour aggressiveness has
been explained, in part, by the delayed generation of 5 hmC on
newly synthesized DNA and the high proliferative rates of
aggressive tumours15. Recent reports have also revealed that
5 hmC may have roles beyond transcriptional regulation. For
example, 5 hmC has previously been shown to localize to DNA
damage in experimental conditions and its role as an epigenetic
marker of DNA damage has been shown to promote genome
stability48. Here, we found that several of the most frequently
mutated genes in glioblastoma including: EGFR, PTEN, NF1,
PIK3R1, RB1, PDGFRA and QKI possessed high 5 hmC levels
across intronic regions and further loss of 5 hmC in tumours may
reﬂect a loss of genome integrity13. In contrast with prior studies,
we did not observe a signiﬁcant association between total 5 hmC
levels and patient survival. While our method for total 5 hmC
measurement was distinct from previous estimations, a lack of
association between survival and global 5 hmC levels suggests that
this relationship is more nuanced than previously thought.
Indeed, we found that subject clusters determined by the
application of RPMM to 5 hmC proﬁles demonstrated
differences in patient survival time with the low-5 hmC
tumours having a signiﬁcantly worst prognosis independent of
subject age. Together, our analysis provides a more complete
understanding of dynamic cytosine modiﬁcations that may
contribute to disease phenotypes and genomic instability.
Not considered by previous studies is the possibility that cancer
cell conservation of 5 hmC may also be critical for glioblastomagenesis and tumour growth as suggested by Takai et al.17. Indeed,
the highest levels of 5 hmC found in this cohort of glioblastomas
were in regions of low CpG-content, a phenomenon also present
in acute myeloid leukaemia and non-diseased tissue22,26,49,50.
Genes with high 5 hmC were noted to be located within actively
transcribed genes in glioblastoma highlighting the role of 5 hmC
as a potential facilitator of transcription. 5 hmC was also
preferentially found in glioblastoma-speciﬁc enhancers and
super-enhancers suggesting that deposition of 5 hmC at these
gene regulatory regions may indicate epigenetic states permissive
to cancer cell survival. Prior work has demonstrated that 5 hmC
modulates enhancer activity and regulates gene expression
programs during cellular differentiation suggesting that 5 hmC
deregulation may impact the dedifferentiation observed in
glioblastoma50–53. The enrichment of cellular identity pathways
in our GREAT analysis and the binding sites of transcription
factors that drive cellular proliferation further supported the link
between 5 hmC and disease-critical gene expression programs.
Indeed, the enrichment of immune response and somatic stem
cell maintenance may reﬂect cellular subpopulations (that is,
glioblastoma stem cells and inﬁltrating immune cells) necessary
for continued tumour growth54. Across this cohort, the consistent
genomic localization of 5 hmC suggests a role for 5 hmC in
genomic regulation of glioblastoma cells that merits future
investigation.
In summary, we have generated nucleotide resolution maps of
5 hmC in thirty glioblastomas and linked 5 hmC with gene
regulatory regions. Our results demonstrate that the glioblastoma

genome exhibits a global loss of 5 hmC compared with healthy
prefrontal cortex tissues, but observed regions of conserved
5 hmC implying novel associations between 5 hmC and critical
tumour transcriptional programs. Our study also highlights that
5 hmC may, in a manner similar to 5 mC, serve as marker of
cellular identity and that genomic patterns reﬂect cellular states in
tissue samples. Thus, methods presented here that deﬁned
associations between 5 hmC distribution and genomic features
may be more broadly applicable to other diseases as well as
characterization of 5 hmC function in non-diseased tissue.
Methods
Study population. Pathologically conﬁrmed fresh frozen glioblastoma specimens
from 30 subjects diagnosed at Dartmouth Hitchcock Medical Center (Lebanon,
NH, USA) between 2004 and 2012 were identiﬁed for study. All subjects provided
written informed consent at the time of surgery for use of their tumour specimens
in research as approved by the committee for protection of human subjects
(Institutional review board). Subject demographic, tumour characteristic and
survival follow-up were available for study and all tissues accessed were from
deceased subjects. This work was performed in accordance with the ethical
principles in the Declaration of Helsinki.
DNA (hydroxy)methylation microarray proﬁling. Tumour DNA was extracted
with the QIAmp DNeasy tissue kit (Qiagen) according to the manufacturer’s
instructions. DNA quantity and quality was assessed with the Qubit 3.0
ﬂuorometer (Life Technologies). Sample DNA was subjected to tandem BS and
oxidative BS (oxBS) conversion with an input of 4 mg per sample using the
TrueMethyl kit v.1.1 (Cambridge Epigenetix) protocol optimized for Illumina
HumanMethylation450 arrays. Prior publications have validated 5 hmC values in
human brain tissue by oxBS-independent approaches and have demonstrated that
replicate samples treated with BS–oxBS display a high level of reproducibility19.
Following quantiﬁcation genomic DNA was sheared to B10 kb fragments using
g-TUBE (Covaris), and puriﬁed with the Gene-JET PCR Puriﬁcation kit (Thermo
Scientiﬁc). A total of1.4 mg was carried forward through oxBS conversion with the
TrueMethyl protocol, and 1.05 mg through the BS conversion arm of the protocol
with manufacturer recommended mass and volume. Recovered substrate ssDNA
was quantiﬁed with Qubit and submitted for DNA methylation array processing at
the UCSF genomics core facility.
IDH1 and IDH2 mutation. All glioblastomas were sequenced for IDH1 (R132) and
IDH2 (R140 and R172) mutation status using PCR ampliﬁcation and Sanger
sequencing. Brieﬂy, 10 ng of genomic DNA was ampliﬁed with primers for each of
IDH1 spanning codon 132: F-GGTGGCACGGTCTTCAGAG, R-ATGTGTTGA
GATGGACGCCT, and IDH2 spanning codons 140 and 172: F-TTCTGGTTGA
AAGATGGCG, and R-GGATGGCTAGGCGAGGAG. Reaction conditions
included a denaturation at 94 °C for 2 min followed by 35 cycles of 94 °C for 30 s,
62 °C for 30 s and 68 °C for 1 min with extension at 68 °C for 5 min as previously
published55.
Data processing and statistical analysis. All data analysis was conducted in R
version 3.1.2. Normalization and background correction of raw signals from each
of the BS and oxBS converted samples was achieved using the FunNorm procedure
available in the R/Bioconductor package minﬁ (version 1.10.2)56. Before analysis
we removed CpG sites on sex chromosomes as well as those corresponding to
probes previously identiﬁed as cross-reactive or containing SNPs57, resulting in
387,617 CpGs remaining for analysis. We applied a novel technique for estimating
5 mC, 5 hmC and unmethylated proportions. Brieﬂy, each CpG corresponded
to a data vector (SBS, RBS, SoxBS, RoxBS), with Rk representing total signal
(unmethylated þ methylated) and representing methylated signal (kA{BS, oxBS});
we used maximum likelihood to ﬁt the data generating model:
SBS  BetaðRBS ðp2 þ p3 Þ; RBS p1 Þ; SoxBS  BetaðRoxBS p2 ; RoxBS ðp1 þ p3 ÞÞ ð1Þ
under the constraints pj40 (jA{1, 2, 3}), p1 þ p2 þ p3 ¼ 1
The resulting estimates parameters (unmethylated proportion), (5 mC
proportion) and (5 hmC proportion). Note that this method explicitly disallows
negative proportions, although we did observe numerically zero values of 5 hmC
(p3o10  16). R code for maximum likelihood estimation as applied to 450 K arrays
is available in the R-package ‘OxyBS’. Since the raw intensity data (IDAT) ﬁles were
unavailable for the prefrontal cortex 5 hmC data set (GSE74368) we processed the
samples using the alternative naı̈ve subtraction method outlined in Houseman
et al.21. The global level of 5 hmC for each sample in both the glioblastoma and
prefrontal cortex samples was determined by summing the 5 hmC beta-values for
all CpGs within in each sample and dividing by the total number of CpGs that
passed quality control metrics and were considered in our analyses (n ¼ 387,617).
For subsequent analysis, we used array annotation available in the
R/Bioconductor packages IlluminaHumanMethylation450kmanifest, version 0.4.0
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and IlluminaHumanMethylation450kanno.ilmn12.hg19, version 0.2.1. In
particular, we classiﬁed each CpG by genomic context (CpG island, shore, shelf or
ocean)58.
We moved to delineate the level at which we could conﬁdently call a genomic
location as possessing bona ﬁde 5 hmC. In our analysis, we deﬁned the locations
within glioblastoma that have the 1% highest mean 5 hmC level to be considered
high 5 hmC CpGs. Next, each CpG was assigned a classiﬁer for high 5 hmC (that is,
0 or 1), putative enhancer regions, open chromatin, Polycomb group target genes,
and gene regions (that is, four separate vectors for promoter, exons, introns or
intergenic) as well as the CpG’s relationship to a CpG island (that is CpG island,
shore, shelf and ocean). Typically, a Fisher’s test is used to test for enrichment of
these features; however, we decided to use the Cochran–Mantel–Haenszel test as
this approach permits stratiﬁcation by CpG island probe type, which we
demonstrated has a substantial impact of the level of 5 hmC.
RNA extraction and gene expression. Tumour RNA was extracted with the
RNeasy Mini tissue kit (Qiagen) according to the manufacturer’s instructions.
Insufﬁcient RNA was available for gene expression from six tumours
(Supplementary Data 4). RNA quantity and quality was assessed with the Qubit 3.0
ﬂuorometer (Life Technologies). The nCounter Analysis System (NanoString
Technologies) was used to simultaneously assess the absolute expression of 41
genes per subject (n ¼ 24). Candidate gene transcripts of interest are presented in
Supplementary Data 4 and were included because one of the following selection
criteria: (i) epigenetic enzymes (that is, DNMT1),48 genes with a high proportion of
CpGs with high 5 hmC in a given gene region with known multiple transcription
splice variants (that is, RGMA 50 UTR), (iii) genes with a known relation to
glioblastoma pathobiology (that is, MGMT) and (iv) glioblastoma housekeeping
genes. The digital multiplexed NanoString nCounter for custom code set was
performed according to manufacturers’ instruction with total RNA. Data
normalization was performed using the nSolver Analysis software (NanoString,
V2.6) with initial positive controls used to normalize all platform associated
sources of variation and reference gene normalization was performed using
housekeeping genes (PUM1, GUSB, TBP, ACTB and SDHA).
Genomic region enrichment analysis. To examine whether high 5 hmC CpGs
were associated with speciﬁc gene sets we used the GREAT software and to query
whether 5 hmC was associated with TFBSs in ENCODE we used the LOLA
software33,59. In both of these analyses, our query input set of genomic regions to
be tested for enrichment were the genomic locations of the high 5 hmC CpGs and
the background set were the genomic locations of the 387,617 CpGs used in the
analysis. The reference database for the GREAT analysis was selected under the
default setting and the ENCODE TFBSs that included 689 different ChIP-seq
experiments was selected for the LOLA analysis.
Estimation of cellular proportions using DNA methylation data. The
RefFreeEWAS algorithm (R-package RefFreeEWAS) is a method for the referencefree deconvolution that provides proportions of putative cell types as deﬁned by
their underlying methylomes60. Previously, this algorithm has been shown to
reasonably estimate the number of constituent cell types61. Moreover,
RefFreeEWAS is a variant of non-negative matrix factorization and is similar to
approaches that use gene expression levels to estimate the proportion of normal
tissue cells in a tumour sample. Brieﬂy, we used the 10,000 most variable CpGs in
terms of their DNA methylation values across all samples (that is, oxBS estimates
alone) and identiﬁed the optimal number of cell types to be three. We then used the
RefFreeCellMix function across all 387,617 CpGs to deﬁne sample-speciﬁc
estimates of cellular proportions. Notably, the glioblastoma samples demonstrated
signiﬁcant proportions of two distinct putative cell types (Supplementary Fig. 3A).
We chose the putative cell-type that explained the greatest variation in cellular
proportions to present estimates of tumour purity.
Copy number alteration calls from Illumina 450 K arrays. To determine
common copy number alterations in primary glioblastomas including: EGFR gain,
CDKN2A loss, chromosome 7 gain and chromosome 10 loss, we used the
Bioconductor package CopyNumber450 K and conﬁrmed copy number gain in
samples where EGFR expression was available.
Deﬁnition of genomic regions. We deﬁned regions of the genome (for example,
introns, exons, promoters) using the UCSC_hg19_refGene ﬁle from the UCSC
Genome Browser and collapsed 5 hmC and 5 mC around the promoter region
using the genomation bioconductor package62.
TCGA glioblastoma gene expression. Level 3 normalized RNAseqV2 expression
levels from TCGA were binned into tertiles based upon mean expression across
all samples. Glioblastoma mRNA splicing data was downloaded from the
TCGASpliceSeq database (that is, mRNA splicing patterns of TCGA RNAseq data).
The data was downloaded from the database with the following ﬁlters: TCGA
disease type was set as glioblastoma, all genes were considered, all TCGA
glioblastoma samples were considered (n ¼ 160 for splicing), all splice events
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(that is, exon skip, alternate promoters and so on), and software speciﬁc ﬁlters of
Percent Splice In value (PSI ¼ number of transcript element reads amid all RNA
sequencing reads covering the splicing event) of 75% and a minimum range of 10
PSI values to identify variable splicing events across tumours.
Code availability. The R code for the OxyBS algorithm can be found in Houseman
et al.21.
Data availability. The glioblastoma 5 hmC and 5 mC DNA microarray data that
support the ﬁndings of this study have been deposited in the Gene Expression
Omnibus (GEO) with the accession code GSE73895 (http://www.ncbi.nlm.nih.gov/geo/).
Five prefrontal cortex samples from individuals with no evidence of
neurological impairment as described in Lunnon et al.28 were accessed on GEO
(GSE74368). Glioblastoma-speciﬁc enhancer and super-enhancer coordinates were
obtained from U87 cells as described in Hnisz et al. (GSE51522)30. Enhancerassociated H3K27ac ChIP-seq coordinates from three freshly resected primary
glioblastoma were processed as described in Suva et al. (GSE54792)63. DNase
hypersensitivity sites in H54 glioblastoma cells (ENCODE) were used to determine
potential areas of open chromatin speciﬁc to the disease (GSM816668). Level 1
TCGA glioblastoma (GBM) 450 K DNA methylation data and associated clinical
data were obtained from the TCGA data portal (http://cancergenome.nih.gov/) and
processed using the minﬁ Bioconductor package56. GBM level 3 gene expression
data from the RNAseqV2 platform were also obtained from the TCGA data portal
(http://cancergenome.nih.gov/). All remaining data is available within the article,
Supplementary Information ﬁles or from the authors upon request.
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